CLDI PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

CLDI ▲ +1.69% at T+5d

SHORT call ✗ call lost -1.69% · α vs SPY -0.48% · entry $0.1770 → $0.1800

Next anchor: T+20d in 13d

Currently $0.1750 · +1.13% from $0.1770 entry (call sign-flipped)

Entry anchored
May 22, 2026
via day open

T+1d

+7.91%

call -7.91% · α -7.90%

$0.1910

settled 15d ago

T+5d

+1.69%

call -1.69% · α -0.48%

$0.1800

settled 9d ago

T+20d

—

call — · α —

—

in 13d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Calidi Biotherapeutics disclosed an audit report with a going-concern emphasis in its 2025 Form 10-K, required by NYSE American Section 610(b). The company, with only a $4M market cap and no approved products, faces a material risk of inability to continue operations without additional capital, and its lead candidate CLD-401 is still in IND-enabling studies. This is a strong negative signal for a pre-revenue biotech with limited cash runway.

Actionable Insight

The going-concern disclosure makes CLDI a high-risk holding. Traders should expect continued downward pressure as the company must raise dilutive capital or face liquidation. Avoid long positions until a material capital infusion or pipeline catalyst materializes. Short interest may already be limited due to tiny float — monitor for OTC delisting.

Key Facts

Audit report on 2025 10-K includes a going-concern explanatory paragraph
Lead candidate CLD-401 remains in IND-enabling studies — no near-term revenue
Market cap is approximately $4M, indicating severe financial distress
Forward-looking statements explicitly flag inadequate capital to support clinical trials
Trading on OTC markets (no NYSE American listing gain) suggests non-compliance or delisting risk
Historical calibration for CLDI reports shows poor win rate (25% T+20) and large negative alpha, consistent with chronic distress bias

Financial Impact

Going-concern qualification implies existential risk for this $4M market cap issuer; no revenue or earnings to quantify

cashRunwaygoingConcernequityValue

Risk Factors

Inability to raise sufficient capital to fund operations in the next 12 months
NYSE American delisting likely (already trading OTC)
Lead asset (CLD-401) is years from potential approval with high clinical risk
Ultra-low market cap creates extreme volatility and liquidity constraints

Market Snapshot

Exchange

OTC

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3300394

6 reports for CLDI

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CLDI — sortable, filterable
	Type				Now
May 26, 2026 14d ago	Press Release NEUTRAL ★ 4/10	$0.1770 $0.1840	▲ +3.95%	▲ +2.87%	$0.1750 (−1.13%)
May 22, 2026 18d ago	Press Release BEARISH ★ 7/10	$0.1770 $0.1800	▼ −1.69%	▼ −0.48%	$0.1750 (+1.13%)
Apr 20, 2026 7w ago	Press Release BULLISH ★ 7/10	$0.2500 $0.2380	▼ −4.80%	▼ −5.71%	$0.1750 (−30.00%)
Mar 27, 2026 10w ago	Press Release MIXED ★ 5/10	$0.2390 $0.2420	▲ +1.26%	▼ −3.04%	$0.1750 (−26.78%)
Mar 10, 2026 13w ago	Press Release BEARISH ★ 7/10	$0.3600 $0.3140	▲ +12.78%	▲ +11.87%	$0.1750 (+51.39%)
Mar 5, 2026 13w ago	Press Release NEUTRAL ★ 4/10	$0.3610 $0.3180	▼ −11.91%	▼ −10.38%	$0.1750 (−51.52%)

US Market Status

Market Closed — Opens Thu (9h 49m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access